Industry Examination of the Hereditary Cancer Testing Market Forecast to 2030 with Top Key Players, Applications and Segmentation


Posted November 29, 2021 by bhandvalkar94

In terms of revenue, hereditary cancer testing market was valued at US$ 6051.37 Mn in 2020 growing at a CAGR of 6.2% over the forecast period (2021 – 2030)
 
A new statistical data titled as Global Hereditary Cancer Testing Market Research Report (2021-2030) has been published by Absolute Markets Insights. Different features of recent trends have been elaborated to give an in-depth analysis of the progress of the industries. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover the accurate data.

For the effective business outlook, it studies different global regions, such as North America, Latin America, Asia-Pacific, Japan, and India by considering different segments such as type, size, as well as applications. SWOT and Porter’s Five analysis have been used to analyze the informative data such as cost, prices, revenue, and end-users. This research report has been aggregated on the basis of various attributes such as manufacturing base, products or services and raw material to understand the requirements of the businesses.

Apart from the regional outlook, it throws light on leading industry key players such as Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE N.V., Color Health Inc., Fulgent Genetics, Illumina Inc., Invitae Corporation, LifeLabs Genetics, Myogenes Limited, Myriad Genetics Inc., NIPD Genetics, and Otogenetics to understand the successful sales strategies of the businesses. Additionally, it covers various factors which is responsible for the progress of the market. For better understanding of ups-down stages of the businesses, analysts also focus on various attributes are limiting the growth of the industries. This comprehensive data provides the guidelines to discover the global opportunities for the Hereditary Cancer Testing sector in the near future.

Browse the full report description, along with the ToCs and List of Facts and Figures @ https://www.absolutemarketsinsights.com/reports/Hereditary-Cancer-Testing-Market-2021---2029-901

Technological advancements for exome sequencing are expected to boost the global hereditary cancer testing market growth as DNA sequencing, along with its advances are paving way in the research field by introducing remarkable advancements in genomics. Compared to whole genome sequencing, the whole exome sequencing is quicker and more cost-efficient. In terms of revenue, hereditary cancer testing market was valued at US$ 6051.37 Mn in 2020 growing at a CAGR of 6.2% over the forecast period (2021 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

As per the cancer type, the global hereditary cancer testing market is segmented into breast cancer, ovarian cancer, colon cancer, stomach cancer, head & neck cancer, prostate cancer, pancreatic cancer, and melanoma, amongst others.

The breast cancer segment accounted for the largest market share in the global hereditary cancer testing market in 2020. Approximately 7% of breast cancer cases are caused by mutations in the BRCA1 or BRCA2 genes. People carrying a mutation in either of these genes suffer from a condition called hereditary breast and ovarian cancer (HBOC) syndrome. They have up to 87% risk of developing breast cancer by age of 70. If the people carrying such mutation have already been diagnosed with cancer, they are significantly at a higher risk of developing a second cancer in the future. Due to advancement in medical science, the early detection of breast cancer along with the adequate treatment is becoming feasible, which is accelerating the growth of the global hereditary cancer testing market. One of the most common cancers in the world, breast cancer affects almost 12.5% of women during their lifetime and 5% to 10% of these patients suffer from this cancer due to hereditary reasons. New advances in genomic technologies have made parallel testing of multiple genes feasible. With customized next generation sequencing panels, the simultaneous analysis of breast cancer predisposition genes is possible. Such genes range from high penetrant genes to intermediate penetrant genes. Thus, this development in genomic technology is estimated to contribute towards the segment’s growth in the global market over the future years.

Global Hereditary Cancer Testing Market: Report Scope

By Cancer Type

Breast Cancer
Ovarian Cancer
Colon cancer
Stomach Cancer
Head & Neck Cancer
Prostate Cancer
Pancreatic Cancer
Melanoma
Others
By Test Type

Single Gene Testing
Multi-Gene Panel Testing
By End Users

Hospitals
Clinics
Diagnostic
Others
By Region

North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Contact Us:

Company: Absolute Markets Insights

Email id: [email protected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

Website: https://www.absolutemarketsinsights.com/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Kavita Sharma
Country India
Categories Business , Research
Tags hereditary cancer testing , hereditary cancer testing market , hereditary cancer testing market research reports , hereditary cancer testing research
Last Updated November 29, 2021